Genovis AB (publ.)
STO: GENO.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Fredrik Olsson
- Employees
- 32
- Headquarters
- Kävlinge, Sweden
- IPO year
- 2008
- Market cap
- SEK 1.3B
- Website
- https://www.genovis.com
Loading GENO…
Loading profile data…Frequently asked questions about GENO
What does Genovis AB (publ.) (GENO.ST) do?
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse...
Where does GENO.ST trade?
Genovis AB (publ.) (GENO.ST) trades on the Stockholm Stock Exchange.
What sector is GENO.ST in?
Genovis AB (publ.) (GENO.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genovis AB (publ.)?
Fredrik Olsson is the chief executive officer of Genovis AB (publ.) (GENO.ST).
Where is Genovis AB (publ.) headquartered?
Genovis AB (publ.) is headquartered in Sweden.
Does GENO.ST pay a dividend?
Genovis AB (publ.) (GENO.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GENO.ST go public?
Genovis AB (publ.) (GENO.ST) completed its initial public offering in 2008.